Which has preferable earnings & valuation, AKTS or QTTB?

Q32 Bio has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aktis Oncology $6.50M 150.09 -$63.73M -$0.82 N/A Q32 Bio $53.74M 4.62 $29.82M $3.00 2.78

Is AKTS or QTTB more profitable?

Q32 Bio's return on equity of 50.17% beat Aktis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Q32 Bio N/A 50.17% 29.49%

Does the media refer more to AKTS or QTTB?

In the previous week, Aktis Oncology had 2 more articles in the media than Q32 Bio. MarketBeat recorded 5 mentions for Aktis Oncology and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.51 beat Aktis Oncology's score of 0.58 indicating that Q32 Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, SVRA or QTTB?

Q32 Bio has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A Q32 Bio $53.74M 4.62 $29.82M $3.00 2.78

Is SVRA or QTTB more profitable?

Q32 Bio's return on equity of 50.17% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Q32 Bio N/A 50.17% 29.49%

Does the media refer more to SVRA or QTTB?

In the previous week, Savara had 3 more articles in the media than Q32 Bio. MarketBeat recorded 6 mentions for Savara and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.51 beat Savara's score of 0.32 indicating that Q32 Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, KURA or QTTB?

Q32 Bio has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kura Oncology $77.23M 12.21 -$278.67M -$3.37 N/A Q32 Bio $53.74M 4.62 $29.82M $3.00 2.78

Is KURA or QTTB more profitable?

Q32 Bio has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Q32 Bio's return on equity of 50.17% beat Kura Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Kura Oncology -384.30% -207.18% -45.17% Q32 Bio N/A 50.17% 29.49%

Does the media refer more to KURA or QTTB?

In the previous week, Kura Oncology had 4 more articles in the media than Q32 Bio. MarketBeat recorded 7 mentions for Kura Oncology and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.51 beat Kura Oncology's score of 0.59 indicating that Q32 Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is QTTB or MLTX more profitable?

Q32 Bio's return on equity of 50.17% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 50.17% 29.49% MoonLake Immunotherapeutics N/A -82.53% -58.17%

Does the media prefer QTTB or MLTX?

In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Q32 Bio. MarketBeat recorded 5 mentions for MoonLake Immunotherapeutics and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.51 beat MoonLake Immunotherapeutics' score of 0.56 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MoonLake Immunotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ANL or QTTB?

Q32 Bio has higher revenue and earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 201.19 -$35.53M N/A N/A Q32 Bio $53.74M 4.62 $29.82M $3.00 2.78

Is ANL or QTTB more profitable?

Q32 Bio's return on equity of 50.17% beat Adlai Nortye's return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Q32 Bio N/A 50.17% 29.49%

Does the media favor ANL or QTTB?

In the previous week, Adlai Nortye had 4 more articles in the media than Q32 Bio. MarketBeat recorded 7 mentions for Adlai Nortye and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.51 beat Adlai Nortye's score of 0.80 indicating that Q32 Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Q32 Bio (QTTB) Competitors

$8.74 +0.40 (+4.80%)

Closing price 04:00 PM Eastern

Extended Trading

$8.86 +0.13 (+1.43%)

As of 07:30 PM Eastern

Compare

QTTB vs. AKTS, SVRA, KURA, MLTX, and ANL

Should you buy Q32 Bio stock or one of its competitors? Q32 Bio's main competitors and comparable companies include Aktis Oncology (AKTS), Savara (SVRA), Kura Oncology (KURA), MoonLake Immunotherapeutics (MLTX), and Adlai Nortye (ANL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Q32 Bio compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Q32 Bio's return on equity of 50.17% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Q32 Bio	N/A	50.17%	29.49%

Q32 Bio has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	150.09	-$63.73M	-$0.82	N/A
Q32 Bio	$53.74M	4.62	$29.82M	$3.00	2.78

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Aktis Oncology had 2 more articles in the media than Q32 Bio. MarketBeat recorded 5 mentions for Aktis Oncology and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.51 beat Aktis Oncology's score of 0.58 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Aktis Oncology presently has a consensus price target of $35.63, suggesting a potential upside of 96.28%. Q32 Bio has a consensus price target of $30.60, suggesting a potential upside of 266.91%. Given Q32 Bio's higher probable upside, analysts plainly believe Q32 Bio is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Q32 Bio beats Aktis Oncology on 10 of the 14 factors compared between the two stocks.

How does Q32 Bio compare to Savara?

Savara (NASDAQ:SVRA) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Q32 Bio's return on equity of 50.17% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Q32 Bio	N/A	50.17%	29.49%

Q32 Bio has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Q32 Bio	$53.74M	4.62	$29.82M	$3.00	2.78

Savara has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

87.9% of Savara shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 34.5% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Savara had 3 more articles in the media than Q32 Bio. MarketBeat recorded 6 mentions for Savara and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.51 beat Savara's score of 0.32 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Savara presently has a consensus target price of $10.25, indicating a potential upside of 108.33%. Q32 Bio has a consensus target price of $30.60, indicating a potential upside of 266.91%. Given Q32 Bio's higher probable upside, analysts plainly believe Q32 Bio is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Q32 Bio beats Savara on 10 of the 14 factors compared between the two stocks.

How does Q32 Bio compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Q32 Bio has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Q32 Bio's return on equity of 50.17% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Q32 Bio	N/A	50.17%	29.49%

Q32 Bio has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$77.23M	12.21	-$278.67M	-$3.37	N/A
Q32 Bio	$53.74M	4.62	$29.82M	$3.00	2.78

31.3% of Q32 Bio shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by insiders. Comparatively, 34.5% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Kura Oncology had 4 more articles in the media than Q32 Bio. MarketBeat recorded 7 mentions for Kura Oncology and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.51 beat Kura Oncology's score of 0.59 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Kura Oncology presently has a consensus target price of $25.69, indicating a potential upside of 142.33%. Q32 Bio has a consensus target price of $30.60, indicating a potential upside of 266.91%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts plainly believe Q32 Bio is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88

Kura Oncology has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Summary

Q32 Bio beats Kura Oncology on 12 of the 17 factors compared between the two stocks.

How does Q32 Bio compare to MoonLake Immunotherapeutics?

Q32 Bio (NASDAQ:QTTB) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Q32 Bio has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Q32 Bio currently has a consensus target price of $30.60, suggesting a potential upside of 266.91%. MoonLake Immunotherapeutics has a consensus target price of $28.50, suggesting a potential upside of 163.40%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts clearly believe Q32 Bio is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88
MoonLake Immunotherapeutics	3 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.43

Q32 Bio's return on equity of 50.17% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

Q32 Bio has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	4.62	$29.82M	$3.00	2.78
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Q32 Bio. MarketBeat recorded 5 mentions for MoonLake Immunotherapeutics and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.51 beat MoonLake Immunotherapeutics' score of 0.56 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MoonLake Immunotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 34.5% of Q32 Bio shares are held by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Q32 Bio beats MoonLake Immunotherapeutics on 11 of the 15 factors compared between the two stocks.

How does Q32 Bio compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Q32 Bio's return on equity of 50.17% beat Adlai Nortye's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Q32 Bio	N/A	50.17%	29.49%

In the previous week, Adlai Nortye had 4 more articles in the media than Q32 Bio. MarketBeat recorded 7 mentions for Adlai Nortye and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.51 beat Adlai Nortye's score of 0.80 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Q32 Bio has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	201.19	-$35.53M	N/A	N/A
Q32 Bio	$53.74M	4.62	$29.82M	$3.00	2.78

Adlai Nortye has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Adlai Nortye currently has a consensus target price of $29.50, indicating a potential upside of 88.86%. Q32 Bio has a consensus target price of $30.60, indicating a potential upside of 266.91%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts plainly believe Q32 Bio is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Q32 Bio beats Adlai Nortye on 8 of the 12 factors compared between the two stocks.

Get Q32 Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QTTB vs. The Competition

Export

Metric	Q32 Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$260.18M	$3.92B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.53%	22.58%
P/E Ratio	2.91	13.45	275.65	25.82
Price / Sales	4.84	1,250.23	622.54	95.26
Price / Cash	5.50	39.46	27.30	36.12
Price / Book	2.56	17.35	10.85	6.10
Net Income	$29.82M	-$22.69M	$3.50B	$380.59M
7 Day Performance	4.42%	-3.32%	-2.14%	-2.34%
1 Month Performance	-21.26%	-9.38%	-4.88%	-4.22%
1 Year Performance	144.82%	12.91%	6.00%	0.54%

Q32 Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QTTB Q32 Bio	3.6087 of 5 stars	$8.74 +4.8%	$32.17 +268.0%	+133.6%	$260.18M	$53.74M	2.91	22	News Coverage Analyst Forecast Gap Up
AKTS Aktis Oncology	2.4056 of 5 stars	$17.86 -3.6%	$35.63 +99.5%	N/A	$959.92M	$10.06M	N/A	79
SVRA Savara	2.1764 of 5 stars	$4.65 -2.7%	$10.00 +115.1%	+46.0%	$955.39M	N/A	N/A	70
KURA Kura Oncology	3.4424 of 5 stars	$10.53 -0.8%	$25.69 +143.9%	+7.6%	$936.76M	$77.23M	N/A	260
MLTX MoonLake Immunotherapeutics	2.5993 of 5 stars	$10.95 -3.8%	$28.50 +160.3%	+5.5%	$931.95M	N/A	N/A	130	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QTTB) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Q32 Bio (QTTB) Competitors

QTTB vs. AKTS, SVRA, KURA, MLTX, and ANL

How does Q32 Bio compare to Aktis Oncology?

Summary

How does Q32 Bio compare to Savara?

Summary

How does Q32 Bio compare to Kura Oncology?

Summary

How does Q32 Bio compare to MoonLake Immunotherapeutics?

Summary

How does Q32 Bio compare to Adlai Nortye?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB vs. The Competition

Q32 Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Q32 Bio (QTTB) Competitors

QTTB vs. AKTS, SVRA, KURA, MLTX, and ANL

How does Q32 Bio compare to Aktis Oncology?

Is AKTS or QTTB more profitable?

Which has preferable earnings & valuation, AKTS or QTTB?

Do institutionals and insiders hold more shares of AKTS or QTTB?

Does the media refer more to AKTS or QTTB?

Do analysts recommend AKTS or QTTB?

Summary

How does Q32 Bio compare to Savara?

Is SVRA or QTTB more profitable?

Which has better valuation & earnings, SVRA or QTTB?

Which has more risk & volatility, SVRA or QTTB?

Do institutionals and insiders have more ownership in SVRA or QTTB?

Does the media refer more to SVRA or QTTB?

Do analysts rate SVRA or QTTB?

Summary

How does Q32 Bio compare to Kura Oncology?

Is KURA or QTTB more profitable?

Which has better valuation & earnings, KURA or QTTB?

Do institutionals and insiders have more ownership in KURA or QTTB?

Does the media refer more to KURA or QTTB?

Do analysts rate KURA or QTTB?

Which has more risk & volatility, KURA or QTTB?

Summary

How does Q32 Bio compare to MoonLake Immunotherapeutics?

Which has more volatility & risk, QTTB or MLTX?

Do analysts prefer QTTB or MLTX?

Is QTTB or MLTX more profitable?

Which has stronger valuation & earnings, QTTB or MLTX?

Does the media prefer QTTB or MLTX?

Do insiders & institutionals hold more shares of QTTB or MLTX?

Summary

How does Q32 Bio compare to Adlai Nortye?

Is ANL or QTTB more profitable?

Does the media favor ANL or QTTB?

Do insiders & institutionals believe in ANL or QTTB?

Which has higher earnings and valuation, ANL or QTTB?

Which has more risk & volatility, ANL or QTTB?

Do analysts prefer ANL or QTTB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB vs. The Competition

Q32 Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools